This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Are You Looking for a High-Growth Dividend Stock? Bristol-Myers Squibb (BMY) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) drugs like Prolia & Xgeva are expected to have done well, slowdown in sales of mature products are likely to have weighed on third-quarter sales.
Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA
by Kinjel Shah
Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) release Q3 results. FDA approves Glaxo's (GSK) Zejula and AstraZeneca's Farxiga for more patients. CHMP gives nod to several drugs
The Extreme Risks of Trading Your Own Retirement Assets - October 25, 2019
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Bristol-Myers Squibb (BMY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Bristol-Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simple Secrets Anyone Can Use to Reach Early Retirement - October 24, 2019
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Factors Setting the Tone for Celgene (CELG) Q3 Earnings
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q3 results.
Bristol-Myers Up as Pivotal NSCLC Study Meets Primary Endpoint
by Zacks Equity Research
Bristol-Myers' (BMY) phase III study evaluating a combination regimen of Opdivo meets primary endpoint of superior overall survival in patients with advanced lung cancer in first-line setting.
The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences
Top Stock Reports for U.S. Bancorp, Bristol-Myers Squibb & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including U.S. Bancorp (USB), Bristol-Myers Squibb (BMY) and Morgan Stanley (MS).
Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $53.20, moving +0.32% from the previous trading session.
What's in Store for Healthcare ETFs in Q3 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Zacks.com featured highlights include: Hasbro, Atkore International, Target, Hibbett Sports and Bristol-Myers Squibb
by Zacks Equity Research
Zacks.com featured highlights include: Hasbro, Atkore International, Target, Hibbett Sports and Bristol-Myers Squibb
Zacks.com featured highlights include: Lowe's, Bristol-Myers Squibb, AECOM and Vulcan Materials
by Zacks Equity Research
Zacks.com featured highlights include: Lowe's, Bristol-Myers Squibb, AECOM and Vulcan Materials
The Extreme Risks of Trading Your Own Retirement Assets - October 17, 2019
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
5 High-Flying Stocks Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
4 Stocks With Upgraded Broker Ratings to Buy Right Away
by Swayta Shah
When brokers upgrade a stock, one can rely on their judgment. Nonetheless, one should also take into account some other factors to ensure steady returns.
Want To Retire Early? Learn the Intelligent Investing Secret - October 16, 2019
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
by Zacks Equity Research
FDA approves Johnson & Johnson's (JNJ) Xarelto to prevent blood clots in hospitalized acutely ill medical patients.
Bristol-Myers Squibb (BMY) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $51.56 in the latest trading session, marking a -0.1% move from the prior day.
Roche Announces Positive Late-Stage Data on Rituxan in PV
by Zacks Equity Research
Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
by Kinjel Shah
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
Is Bristol-Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.
Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook
by Zacks Equity Research
Goldman Sachs lowers price target for Clovis' (CLVS) shares taking into account the risk of lower future revenues due to rising competition in the PARP inhibitor segment.
Nektar's Shares Drop on Rating Downgrade by Goldman Sachs
by Zacks Equity Research
Nektar (NKTR) continues its downfall in 2019. Goldman Sachs downgrades the company's rating from Buy to Sell.